Tracers / [68Ga]PKB3

[68Ga]PKB3

Also written as [Ga-68]Ga-PKB3

Radionuclide: Ga-68 t½ 67.71 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer Receptor expression phenotyping

What it is

Compound class: DOTA-conjugated GRPR-targeting peptide (RM26 analogue)
Target / mechanism: Gastrin-releasing peptide receptor (GRPR) antagonist/binder PMID 41701408
Clinical application: PET imaging of GRPR-positive tumours as diagnostic counterpart in a 177Lu/68Ga theranostic pair for prostate cancer PMID 41701408
Theranostic pair: —

Regulatory status

FDA: —
EMA (centralised): —
Other approvals: —
Brand names: —

Clinical use

Typical injected activity: —
Uptake time: —

Reported in the literature. Not a dosing recommendation.

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	>99%	>97%	PKB3 (DOTA-PEG2-Pip-[MetTrp8, Sar11]RM26) Pepmic Co., Ltd., Suzhou, China	41701408 2026 EJNMMI Radiopharm Chem The labelling of AU-RM26-M2, PKB2, and PKB3 with Ga-68 was performed by adding 250 µL of freshly eluted Ga-68 (70–80 MBq, measurement after labelling) to a solution containing 5 nmol of peptide, 125 µL EtOH (99.5%), and 30 µL NH4OAc (1 M, pH 4.5). — [68Ga]Ga-PKB2 and [68Ga]Ga-PKB3 were produced with radiochemical yields over 99%

Need this precursor?We can point you to suppliers for [68Ga]PKB3, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 41701408. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 41701408: 'PKB3 [DOTA-PEG2-Pip-[MetTrp8, Sar11]RM26]'.